Overview

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

Status:
Completed
Trial end date:
2021-09-12
Target enrollment:
Participant gender:
Summary
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.
Phase:
N/A
Details
Lead Sponsor:
Sinotau Pharmaceutical Group